Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Using block chain technology, Nebeus is a growing cryptographic platform for the global stage. Nearly 30,000 wallets are active, which has resulted in £1.9m of P2P bitcoin loans facilitated on the service since 2017. The company has launched a cryto-card for users to utilise both cryto currency, as well as fiat money. Nebeus currently operates in 45 countries with over £30m transactions to date and plans to expand into other major markets soon.
days to go:
Expired
investment:
£1,211,700
Lime Global is a UK-based company dedicated to becoming the most customer-focused provider of health cover. Lime argues that conventional health insurance is too expensive and overly complicated. It intends to make health insurance affordable allowing customers to buy the top-ups they want without consulting advisers or filling long questionnaires. Lime Global claims to provide customers with a cancer cover providing a lump sum and support following diagnosis, access to 'Rapid Diagnostics' to avail private diagnostic tests, and an online platform where customers and employers can book and pay for clinical services. Lime Global aspires to become a contender in the UK private healthcare market set to grow more than £8 billion. The company points out that it has secured 5 star Trustpilot reviews over the last year with zero complaints to date. They intend to use the investment to support their expansion into Small and Medium Enterprises (SMEs), mental health modules and e-pharmacies, scale customer acquisition, and support the next stage of its growth in late 2021 and early 2022.
days to go:
Expired
investment:
£474,838
A multi-award winning investment platform providing customers with ISA eligible loans. Crowdstacker are fully FCA regulated and set a record for the largest crowdfunded P2P loan in the UK, valued at £15m. With the recent release of Innovative Finance ISA, the company is expecting to see rapid growth in the near future.
days to go:
Expired
investment:
£818,210
Growth Capital Ventures (GCV) is a Financial Conduct Authority (FCA) approved fintech company. GCV's mission is to back the game changers, innovators and value creators. It is operating at three different levels namely, G-Ventures, a specialist software development division; Quva, a private investor network; and G- Labs, an innovation lab. The company aims to provide investors with access to well researched alternative investment opportunities that are selected for their potential to deliver better returns than traditional mainstream investment products. GCV has structured property transactions worth £14.7 million, has 5000+ everyday investors, and seen 500+ jobs created by portfolio companies. GCV will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£1,295,410
The Clubhouse is a professional space that offers an alternative meeting place for businesses of all sizes. Also, it offers complimentary WiFi, refreshments, tea, Nespresso coffee and a dedicated team to help out.
days to go:
Expired
investment:
£950,915
10Cast forensic forecasting is a cloud and mobile AI application that integrates with legacy CRM systems to improve B2B forecasting.
days to go:
Expired
investment:
£90,056
